Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders

Yesterday, June 6, 2016, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $185.85 to $2,531,705.11.

Highlighted Stocks Traded by Insiders:

Mylan (MYL) - FREE Research Report

Maroon Joseph C Md, who is Director at Mylan, bought 1,670 shares at $44.95 on June 6, 2016. Following this transaction, the Director owned 22,036 shares meaning that the stake was boosted by 8.2% with the 1,670-share transaction.

The shares most recently traded at $45.98, up $1.03, or 2.24% since the insider transaction. Historical insider transactions for Mylan go as follows:

  • 4-Week # shares bought: 3,560
  • 4-Week # shares sold: 217,755
  • 12-Week # shares bought: 9,602
  • 12-Week # shares sold: 217,755
  • 24-Week # shares bought: 24,979
  • 24-Week # shares sold: 217,755

The average volume for Mylan has been 5.2 million shares per day over the past 30 days. Mylan has a market cap of $22.6 billion and is part of the health care sector and drugs industry. Shares are down 13.96% year-to-date as of the close of trading on Monday.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The stock currently has a dividend yield of 0.54%. The company has a P/E ratio of 27.8. Currently, there are 5 analysts who rate Mylan a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MYL - FREE

TheStreet Quant Ratings rates Mylan as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Mylan Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Parker Drilling (PKD) - FREE Research Report

King Gary R, who is Director at Parker Drilling, sold 6,400 shares at $2.20 on June 6, 2016. Following this transaction, the Director owned 108,503 shares meaning that the stake was reduced by 5.57% with the 6,400-share transaction.

The shares most recently traded at $2.36, up $0.16, or 6.7% since the insider transaction. Historical insider transactions for Parker Drilling go as follows:

  • 4-Week # shares bought: 40,000
  • 4-Week # shares sold: 2,071
  • 12-Week # shares bought: 40,000
  • 12-Week # shares sold: 2,071
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 2,071

The average volume for Parker Drilling has been 580,800 shares per day over the past 30 days. Parker Drilling has a market cap of $271.5 million and is part of the basic materials sector and energy industry. Shares are up 29.12% year-to-date as of the close of trading on Monday.

Parker Drilling Co, together with its subsidiaries, provides contract drilling and drilling-related services, and rental tools to the energy industry in the United States, Latin America, Europe, the Middle East, Africa, Asia, Russia, the Commonwealth of Independent States, and internationally. Currently, there are no analysts who rate Parker Drilling a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PKD - FREE

TheStreet Quant Ratings rates Parker Drilling as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and weak operating cash flow. Get the full Parker Drilling Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medivation (MDVN) - FREE Research Report

Powell Andrew Kenneth William, who is SVP, General Counsel & Crp Sec at Medivation, sold 2,578 shares at $60.42 on June 6, 2016. Following this transaction, the SVP, General Counsel & Crp Sec owned 28,517 shares meaning that the stake was reduced by 8.29% with the 2,578-share transaction.

The shares most recently traded at $59.69, down $0.73, or 1.22% since the insider transaction. Historical insider transactions for Medivation go as follows:

  • 4-Week # shares sold: 10,340
  • 12-Week # shares sold: 10,340
  • 24-Week # shares sold: 35,363

The average volume for Medivation has been 3.8 million shares per day over the past 30 days. Medivation has a market cap of $10.0 billion and is part of the health care sector and drugs industry. Shares are up 23.36% year-to-date as of the close of trading on Monday.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company has a P/E ratio of 38.5. Currently, there are 9 analysts who rate Medivation a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDVN - FREE

TheStreet Quant Ratings rates Medivation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Medivation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

The U.S. Economy Is 'Stronger Than Most People Realize': LIVE BLOG

The U.S. Economy Is 'Stronger Than Most People Realize': LIVE BLOG

Goldman Takes Wall Street Trading Title After Sputtering Last Year

Goldman Takes Wall Street Trading Title After Sputtering Last Year

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

Stocks Push to Session Highs During Fed Chair's Congressional Testimony

This Under the Radar Stock Picker Tells Jim Cramer He Is Bullish on Citigroup

This Under the Radar Stock Picker Tells Jim Cramer He Is Bullish on Citigroup

Morgan Stanley Profit Surges 38% on Trading Revenue, Tax Cuts

Morgan Stanley Profit Surges 38% on Trading Revenue, Tax Cuts